Published in Healthcare Finance, Tax and Law Weekly, December 6th, 2006
The trial compared CRx-102 plus a disease-modifying anti-rheumatic drug (DMARD) to placebo plus DMARD (control) in subjects with RA. In this trial, CRx-102 demonstrated statistically significant improvements on primary and secondary endpoints:
- CRP: 50% median reduction from baseline to day 42 compared to 19% with control (p=0.024)
- ACR 20: 63% response at day 42 compared to 30% with control (p=0.025)
- DAS28: -1.6 mean change...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.